Healthcare Industry News:  liposome 

Biopharmaceuticals Personnel

 News Release - September 27, 2007

Celsion Bolsters Clinical Development Team

COLUMBIA, Md.--(HSMN NewsFeed)--CELSION CORPORATION (AMEX: CLN ) today announced the appointment, effective October 1, 2007, of Nicholas Borys, M.D. to the position of Vice President and Chief Medical Officer. In this position Dr. Borys will manage the clinical development program for Celsion.

Dr. Borys, who was most recently Chief Medical Officer at Molecular Insight Pharmaceuticals, Inc., has accumulated extensive experience in oncology and all phases of pharmaceutical development while holding increasingly senior positions at Taiho Pharma USA, Cytogen Corporation, Anthra Pharmaceuticals, Inc., Amersham Healthcare, Inc. and Hoffmann La-Roche Inc.

Dr. William Hahne, Celsion's Vice President, Clinical and Medical Affairs will collaborate with Dr. Borys on developing Celsion's clinical strategy for its current primary liver cancer and recurrent breast cancer at the chest wall pivotal programs. In addition, they will explore and identify additional indications for ThermoDox®, the company's proprietary heat activated liposomal formulation of doxorubicin, as well as other chemotherapeutic drugs, based on the company's unique heat activated liposome platform technology.

Michael H. Tardugno, Celsion's President and Chief Executive Officer commented, "We are delighted that Dr. Borys has joined our team. Dr. Borys has a wealth of clinical development experience with a strong focus on oncology, and will be very valuable to the company as it initiates its primary liver cancer pivotal study, and develops plans to advance the recurrent breast cancer at the chest wall program to a pivotal study."

Mr. Tardugno added, "Dr. Borys' addition is in line with our focus of building an organization with the clinical and scientific competencies to execute our strategy. Both Dr. Hahne and Dr. Borys have extensive experience in the oncology arena. The product of their collective strength and experience should prove to be a very valuable asset for Celsion."

About Celsion:

Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, North Shore Long Island Jewish Health System. Additional information about Celsion Corporation can be found on the Celsion web site at www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.


Source: Celsion

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.